Dopamine Receptor 1 Impedes ILC2-Mediated Antitumor Immunity

In this study, we report that dopamine receptor 1 (DRD1) restrains ILC2 activity in the TME. DRD1 deficiency promotes ILC2 activation, which irritates eosinophil recruitment and cytotoxic CD8+ T cell expansion during ongoing malignancy. Consequently, DRD1-deficient mice exhibit delayed tumor growth and reduced tumor progression. Furthermore, fenoldopam, a selective DRD1 agonist, restrains the ILC2 response in the TME and aggravates tumor burden in mice. Taken together, our data elaborate that the DRD1 signal acts as an excitatory rheostat in regulating ILC2-dependent antitumor immunity.PMID:37728417 | DOI:10.4049/jimmunol.2300220

Source: Journal of Immunology - September 20, 2023 Category: Allergy & Immunology Authors: Xiangyang Wang Xiangyu Chen Jierong Chen Chunhui Liao Xiaofan Yang Jiasheng Zhou Shanshan Liu Shusen Ye Yuhao Zheng Linzi Huang Jiacong Zhao Lilin Ye Bihui Huang Yingjiao Cao Source Type: research